Alvotech (ALVO) announced key senior leadership changes following a planned succession process. Founder Robert Wessman, who has served as Chairman since the company’s inception in 2013 and CEO since 2023, will transition out of the CEO role at the end of the first quarter of 2026. He will continue to serve as Executive Chairman in a full-time capacity. Lisa Graver has been appointed as his successor as CEO. She served as CEOO of Alvogen until its acquisition by Lotus Pharmaceutical in December 2025, and as a member of Alvotech’s Board since its public listing in 2022. The transition process will begin immediately, with Ms Graver working closely with Mr Wessman and the executive team over the coming months to ensure continuity and a smooth handover. Upon assuming the CEO role, she will step down from the Alvotech Board.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALVO:
- Alvotech Raises USD 100 Million Term Loan to Bolster Biosimilar Growth and 2026 Launches
- Alvotech Begins European Rollout of First-Ever Simponi Biosimilar Gobivaz
- Alvotech and Teva Settle With Regeneron on U.S. Launch Timing for Eylea Biosimilar AVT06
- Alvotech, Teva reach settlement and license agreement with Regeneron for AVT06
- Alvotech Completes $108 Million Convertible Bond Offering to Drive R&D and Biosimilar Launches